Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Aug 28, 2012 (14 years ago)

Preservative-Free MORPHINE Sulfate Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: Loose crimp applied to the fliptop vial

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Preservative-Free MORPHINE Sulfate Injection, USP, 10 mg/10 mL (1 mg/mL) 10 mL vial, Rx only, HOSPIRA, INC, LAKE FOREST, IL 60045 USA NDC 0409-3815-12

Affected NDC 0409-3815-12

Compare with the code on your package — it is the most precise check available.

Drug: Morphine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Morphine Sulfate
NDC 00409-3815
1 mg/mL Injection, Solution
Epidural|intrathecal|intravenous
Hospira, Inc. Rx · CII
Recalling firm
Hospira Inc.
NDC code
0409-3815-12
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-308-2013 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Morphine recalls

See all
Class I · High risk

Morphine Sulfate Injection

Labeling: Label Mixup: MicroVault labeled as Morphine 2 mg/1 mL, contains a Prefilled Syringe of Dilaudid 0.5 mg/0.5 mL.

Ongoing Labeling / mix-up Fresenius Kabi USA, LLC D-0788-2026

Other recalls by Hospira Inc.

All 2012 recalls
Class II · Moderate risk

DOBUTamine Injection

Discoloration: Firm received complaints of product discoloration and particulates.

Terminated Failed specification Hospira Inc. NDC 0409-2025-20 D-1500-2016